News

Following the acquisition, the plant will be licensed to produce N-acetylgalactosamine 6-sulfatase (GALNS) by 2015. BioMarin CEO Jean-Jacques Bienaime said they believe that additional manufacturing capabilities beyond their

Glybera is used to treat patients with the genetic disorder lipoprotein lipase deficiency (LPLD). AMT CEO Jorn Aldag said they believe that there is an indication from the

Earlier in February, Pfizer said it would close operations at the site. The US based drug maker’s intent was to outsource some R&D activities and colleagues at the

SBC-102, which is under clinical trials, is a recombinant human lysosomal acid lipase enzyme responsible for the breakdown of cholesteryl esters and triglycerides. Synageva R&D CMO and head

The company had provided only non-GLP services focused on early stage research and discovery. Aragen Bioscience specializes in recombinant cell line and hybridoma development, cell culture and protein

Zyclara cream is indicated for the treatment of actinic keratosis (AK) on the face and scalp. Meda CEO Anders Lonner said Zyclara will strengthen Meda’s dermatology franchise in

Under the agreement, Evotec will use PhosphoScout platform for discovery of protein-phosphorylation’s that predict favorable dosage and efficacy of targeted cancer drugs in patients. Evotec’s PhosphoScout platform uses

Orient Europharma intends to team up with 6 other Taiwanese clinical centers for conducting the study, named as immunotherapy Multikine anti tumor treatments (IT-MATTERS), which is already ongoing

The lawsuit was filed in connection with the abbreviated new drug application (ANDA) for Budesonide Capsules, 3mg, a generic version of AstraZeneca’s Entocort EC capsules. The US District